BD Pharmingen- FITC Mouse Anti-Human IL-12 -p40-p70_BD Pharmingen
参考图片
Expression of IL-12 p40/p70 by activated CD14 + human PBMCs. Ficoll™-separated human PBMCs were primed for 2 hours with recombinant human IFN-γ (10 ng/ml final concentration; Cat. No. 554616), then activated with IFN-γ (10 ng/ml final concentration) and LPS (100 ng/ml final concentration; Sigma) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554724) for an additional 22 hours. Cells were harvested, stained with PE-mouse anti-human CD14 antibody (Cat. No. 555398), fixed, permeabilized, and then stained with 0.125 µg of FITC-C11.5 antibody (Cat. No. 554574), following the BD Pharmingen staining protocol (left panel). The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding of FITC-C11.5 antibody was blocked by preincubation of the conjugated antibody with recombinant human IL-12 p70 (Cat. No. 554613; middle panel) and by preincubation of the fixed/permeabilized cells with unlabeled C11.5 antibody (Cat. No. 554573; right panel) prior to staining with the FITC-C11.5 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabelled antibody blocking specificity controls.
Expression of IL-12 p40/p70 by activated CD14 + human PBMCs. Ficoll™-separated human PBMCs were primed for 2 hours with recombinant human IFN-γ (10 ng/ml final concentration; Cat. No. 554616), then activated with IFN-γ (10 ng/ml final concentration) and LPS (100 ng/ml final concentration; Sigma) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554724) for an additional 22 hours. Cells were harvested, stained with PE-mouse anti-human CD14 antibody (Cat. No. 555398), fixed, permeabilized, and then stained with 0.125 µg of FITC-C11.5 antibody (Cat. No. 554574), following the BD Pharmingen staining protocol (left panel). The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding of FITC-C11.5 antibody was blocked by preincubation of the conjugated antibody with recombinant human IL-12 p70 (Cat. No. 554613; middle panel) and by preincubation of the fixed/permeabilized cells with unlabeled C11.5 antibody (Cat. No. 554573; right panel) prior to staining with the FITC-C11.5 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabelled antibody blocking specificity controls.
本文来自投稿,不代表本人立场,如若转载,请注明出处:http://www.iamyjet.com/kangti/9665.html